King Pharmaceuticals, Wyeth amend Altace agreement

Share this article:
King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King's Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure. Effective Jan. 1, 2007, King will assume full responsibility for the selling and marketing of Altace. For the remainder of 2006, the Wyeth sales force will continue to promote the product with King, and Wyeth will receive a fee thereafter through 2010.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.